For a molecule to serve as a potent and effective treatment for onychomycosis, it must readily penetrate the human nail plate and reach the site of infection. This has been an enormous hurdle for many products. HXP124 penetrates the human nail plate and preliminary data indicates that it does so with greater efficiency than current therapies used to treat onychomycosis. On average, over 16% of the applied dose penetrated through the nail plate by day 10 compared with less than 3% for efinaconazole (Jublia®). High amounts of HXP124 can also be detected in the nail plate, both at the site of dosing and 5 mm from the dosed area, demonstrating that HXP124 moves laterally through the nail plate. This is important as HXP124 is likely to reach areas of the nail that are under the nail folds where fungal cells may evade topical products with poor nail penetration and diffusion. The faster and more efficient penetration of HPX124 through nails makes it a superior candidate for the treatment of fungal nail infections and may allow for shorter treatment times.